• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Quanterix Appoints Michael Doyle as Chief Financial Officer

    6/28/21 4:08:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $QTRX alert in real time by email

    Doyle brings strong financial experience and track record to Quanterix

    Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has named Michael Doyle to the position of Chief Financial Officer (CFO) and Treasurer, effective July 12, 2021. Doyle replaces Shawn Stetson, who has served as the Company's Interim Chief Financial Officer and Treasurer.

    "Mike is a strong financial executive with deep experience serving as a public company CFO, and in light of our company's continued growth and opportunity to transform healthcare through our non-invasive early detection technology, we welcome his business acumen as we scale and strengthen our executive team with top talent," said Kevin Hrusovsky, Chairman and Chief Executive Officer, Quanterix and Founder of Powering Precision Health Foundation. "Mike's track record for driving organic and inorganic growth coupled with his strong experience scaling businesses processes and financial organizations is a rare find and should serve us well as we scale our research and diagnostic opportunity."

    In his most-recent role as CFO at Forrester Research, Mike managed a global team of 85 professionals and completed seven acquisitions in 13 years, including the recent acquisition and integration of SiriusDecisions in 2019. At Forester, Mike was responsible for implementing new systems and processes that enabled the company to grow from $200M to $500M in revenue. Prior to Forrester, Mike served as CFO of EasyLink Services, where he led a 50-person finance organization responsible for finance, accounting, human resources and information systems.

    "I've long admired the work of Quanterix and its strategic potential to help revolutionize healthcare and precision health," said Doyle. "From the company's mission to its people, I am eager to join Quanterix and help fulfill its "life changing" vision. I am excited to join such an impressive leadership team and help shape the Company's future and realize it's incredible potential."

    For more information on Quanterix please visit: www.quanterix.com

    About Quanterix

    Quanterix is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health. The company's digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix' expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix' actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix' filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005786/en/

    Get the next $QTRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QTRX

    DatePrice TargetRatingAnalyst
    2/1/2024$30.00Sector Outperform
    Scotiabank
    9/25/2023$25.00 → $32.00Hold → Buy
    Canaccord Genuity
    8/8/2023$30.00Market Perform → Outperform
    SVB Securities
    5/23/2023$13.00 → $27.00Neutral → Buy
    Goldman
    8/15/2022$40.00 → $12.00Buy → Hold
    Canaccord Genuity
    8/9/2022$38.00 → $18.00Outperform → Market Perform
    Cowen
    8/9/2022$35.00 → $15.00Outperform → Mkt Perform
    SVB Leerink
    3/2/2022$85.00 → $60.00Overweight
    JP Morgan
    More analyst ratings

    $QTRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Quanterix with a new price target

      Scotiabank initiated coverage of Quanterix with a rating of Sector Outperform and set a new price target of $30.00

      2/1/24 6:32:54 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Quanterix from Hold to Buy and set a new price target of $32.00 from $25.00 previously

      9/25/23 9:03:48 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix upgraded by SVB Securities with a new price target

      SVB Securities upgraded Quanterix from Market Perform to Outperform and set a new price target of $30.00

      8/8/23 6:29:03 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders

      RINCON, Puerto Rico, June 11, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement condemning the Company's failure thus far to schedule its 2025 Annual Meeting on time. "Quanterix's ongoing failure to schedule its 2025 Annual Meeting until the approaching legal deadline is consistent with the Board's pattern of limiting and disregarding shareholder input. More than one year has already passed since Quanterix held its last Annual Meeting on June 3, 2024, yet the 2025 Annual Meeting remains unscheduled. We believe the Board

      6/11/25 8:00:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix to Present at Goldman Sachs Global Healthcare Conference

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be accessed from the Investors section of the company's website at www.quanterix.com. A replay of the webcast will be available for a limited period following the conference. To learn more about Quanterix, visit www.qu

      6/6/25 9:41:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

      RINCON, Puerto Rico, May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's Post-Effective Amendment to its S-4 registration statement and Akoya Biosciences' ("Akoya") (NASDAQ:AKYA) disclosure of an unsolicited all-cash offer at $1.40-per-share. "Quanterix's amended merger terms (the "Amended Merger Agreement"), structured to avoid a shareholder vote, already commit the company to pay $20 million in cash alongside 8.4 million newly issued shares in its misguided pursuit of Akoya. On May 20, 20

      5/23/25 2:21:00 PM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Walt David R bought $984,968 worth of shares (160,000 units at $6.16), increasing direct ownership by 9% to 1,866,933 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/13/25 4:39:15 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President & CEO Toloue Masoud bought $248,723 worth of shares (45,900 units at $5.42), increasing direct ownership by 10% to 518,922 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/10/25 4:08:44 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Walt David R bought $1,133,796 worth of shares (210,000 units at $5.40), increasing direct ownership by 14% to 1,706,933 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/9/25 5:44:04 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Walt David R bought $984,968 worth of shares (160,000 units at $6.16), increasing direct ownership by 9% to 1,866,933 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/13/25 4:39:15 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President & CEO Toloue Masoud bought $248,723 worth of shares (45,900 units at $5.42), increasing direct ownership by 10% to 518,922 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/10/25 4:08:44 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Walt David R bought $1,133,796 worth of shares (210,000 units at $5.40), increasing direct ownership by 14% to 1,706,933 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/9/25 5:44:04 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $QTRX
    SEC Filings

    See more

    $QTRX
    Financials

    Live finance-specific insights

    See more

    $QTRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Amendment: SEC Form SC 13G/A filed by Quanterix Corporation

      SC 13G/A - Quanterix Corp (0001503274) (Subject)

      11/13/24 12:41:46 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Quanterix Corporation

      SC 13G - Quanterix Corp (0001503274) (Subject)

      6/27/24 2:46:59 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Quanterix Corporation (Amendment)

      SC 13G/A - Quanterix Corp (0001503274) (Subject)

      2/14/24 4:57:53 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form EFFECT filed by Quanterix Corporation

      EFFECT - Quanterix Corp (0001503274) (Filer)

      6/13/25 12:15:03 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form POS AM filed by Quanterix Corporation

      POS AM - Quanterix Corp (0001503274) (Filer)

      6/3/25 9:24:17 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Quanterix Corporation

      SD - Quanterix Corp (0001503274) (Filer)

      6/2/25 4:50:04 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Releases Financial Results for the First Quarter of 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward," said Masoud Toloue, CEO of Quanterix. "Today, we are excited to announce a major advance: through a new early-access program, Simoa® ONE assay kits will become compatible with over 20,000 existing flow cytometers worldwide—significantly reducing the need for capital equipment purchases by current and future customers. This leap is enabled by

      5/12/25 4:01:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, May 12, 2025, at 4:30 p.m. E.T., to discuss its first quarter 2025 financial results. Quanterix will issue a press release regarding its first quarter 2025 financial results prior to the conference call on Monday, May 12, 2025, after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 7353673. Interested investors can also access the live we

      5/5/25 7:00:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Releases Financial Results for the Fourth Quarter of 2024

      Delivers seventh consecutive quarter of double-digit revenue growth Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter ended December 31, 2024. "During the fourth quarter, we delivered 11% revenue growth, our seventh straight quarter of double-digit growth, despite a capital constrained environment," said Masoud Toloue, Chief Executive Officer of Quanterix. "Our ability to grow in a difficult environment is the result of investments in our business model, which focuses on key vertical markets and recurring revenues. We are expanding our approach to immunology and

      3/17/25 4:01:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Expands Capabilities with Strategic Acquisition of EMISSION

      Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the acquisition of EMISSION iNC. ("EMISSION"). Quanterix expects the transaction will close in January 2025. "As we expand our technology stack toward higher multi-plex and multi-omic capabilities, it is imperative we control core components," said Masoud Toloue, Chief Executive Officer of Quanterix. "EMISSION's proprietary bead technology has already been validated on our upcoming new Simoa platform and will en

      12/17/24 6:59:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors. Dr. Magovčević-Liebisch brings more than 25 years of biopharmaceutical industry experience, including founding Vigil Neuroscience, Inc. four years ago, where she serves as President and Chief Executive Officer. Under her leadership, Vigil raised more than $350 million and advanced its lead pipeline candidates into clinical development, including the first clinical-stage small molecule TREM2 agonist for the potential treatment of Alzheimer's dis

      10/2/24 4:00:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials